Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.

Trial Details

NCT ID
NCT07358806
Phase
PHASE1
Sponsor
Oscotec Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • OCT-598
  • Docetaxel
Locations (sample)
  • Goyang-si, South Korea|37.65639,126.835
  • Seongnam-si, South Korea|37.43861,127.13778
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Female or male, ≥18 years of age (or ≥19 years according to according to the local regulatory guidance), at the time of screening
  • Signed informed consent prior to any study-related procedures that are not considered standard of care
  • Life expectancy \>12 weeks in the opinion of the investigator
  • Adequate organ and marrow function, defined as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →